Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: The majority of anal cancers (84-95%) are driven by infection with human papillomavirus (HPV). HPV-positive tumours show significantly better responses to chemo-radiotherapy when compared with HPV-negative tumours. HPV infection is linked to alterations in DNA damage response proteins, including MRE11. MRE11 is a potential predictive biomarker for response to radiotherapy in muscle-invasive bladder cancer and may hold predictive power in other cancers. METHODS: Using a previously reported cohort, we evaluated the levels of MRE11 in anal cancer and assessed its predictive value in this disease. RESULTS: We found no association between the level of MRE11 and relapse-free survival following chemo-radiotherapy. CONCLUSIONS: MRE11 has no predictive value in the analysis of relapse-free survival after chemo-radiotherapy in anal cancer and does not add to the prognostic value of p16 and tumour-infiltrating lymphocyte scores. Further investigation into the role of DNA repair proteins in anal cancer is required.

Original publication

DOI

10.1038/bjc.2017.188

Type

Journal article

Journal

Br J Cancer

Publication Date

25/07/2017

Volume

117

Pages

322 - 325

Keywords

Anus Neoplasms, Biomarkers, Tumor, Carcinoma, Squamous Cell, Chemoradiotherapy, Cyclin-Dependent Kinase Inhibitor p16, DNA-Binding Proteins, Disease-Free Survival, Female, Humans, Male, Predictive Value of Tests, Tumor Suppressor Protein p53